How TRT Impacts Hepatic Glucose Metabolism & Metabolic Health

Why the Liver Is Central to Testosterone's Metabolic Effects

The liver produces roughly 80 percent of fasting blood glucose through glycogenolysis and gluconeogenesis, making it the dominant target organ for any intervention that improves whole-body glucose control. Testosterone acts directly on hepatocytes through androgen receptors, suppressing the transcription of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase, the two rate-limiting enzymes in gluconeogenesis.

Androgen Receptors in Hepatocytes

Hepatocytes express functional androgen receptors (ARs), a fact confirmed by immunohistochemistry studies in human liver biopsy tissue. When testosterone binds hepatic ARs, it down-regulates the transcription factors that drive gluconeogenesis, specifically forkhead box protein O1 (FOXO1) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha). A 2019 mechanistic study published in the Journal of Hepatology showed that AR-knockout male mice developed fasting hyperglycemia and elevated PEPCK activity within 8 weeks of androgen deprivation, and these changes were fully reversible with dihydrotestosterone (DHT) restoration [1].

Insulin Receptor Signaling in the Low-Testosterone State

Men with total testosterone below 300 ng/dL show consistent impairment of the hepatic insulin receptor substrate-1 (IRS-1) phosphorylation cascade. This means even normal portal insulin concentrations cannot adequately suppress hepatic glucose output (HGO). The result is elevated fasting glucose independent of pancreatic beta-cell dysfunction. A cross-sectional analysis of 2,100 men in the European Male Ageing Study (EMAS) found that men in the lowest testosterone quartile had fasting glucose values 12 mg/dL higher and HOMA-IR scores 1.8 units greater than men in the highest quartile, after adjusting for BMI and age [2].

What TRT Does to Hepatic Glucose Output Specifically

Euglycemic-hyperinsulinemic clamp studies in hypogonadal men before and after 6 months of testosterone undecanoate (1,000 mg IM every 12 weeks) show a 22 to 30 percent reduction in basal HGO rates. That reduction is additive to the peripheral glucose uptake improvements in skeletal muscle. Together, the hepatic and peripheral effects explain the HbA1c reductions observed in clinical trials without requiring changes in diet or exercise.

Key Clinical Trial Data on TRT and Glycemic Control

Several randomized controlled trials and large observational registries have directly measured glycemic endpoints in men receiving TRT. The data are consistent in direction, though effect sizes vary by baseline testosterone, diabetes status, and treatment duration.

The Testosterone Trials (TTrials)

The Testosterone Trials were a coordinated set of seven double-blind, placebo-controlled trials in 788 men aged 65 or older with total testosterone below 275 ng/dL. The Physical Function Trial and the Bone Trial both collected metabolic secondary endpoints. Men receiving testosterone gel 1% (dose-adjusted to achieve levels of 500 to 800 ng/dL) showed a 10.8 percent reduction in fasting insulin and a 0.4 percentage point reduction in HbA1c compared with placebo after 12 months. The difference in HbA1c did not reach statistical significance in the full cohort but was significant in the pre-specified subgroup with baseline HbA1c above 6.0 percent (P<0.04) [3].

The Registry of Hypogonadism in Men (RHYME) and Long-Term Observational Data

The RHYME registry followed 999 hypogonadal men across eight European countries for up to 24 months. Men treated with testosterone undecanoate showed mean HbA1c reductions of 0.58 percentage points by month 12 and 0.86 percentage points by month 24. Fasting glucose dropped by an average of 14 mg/dL. Men who discontinued therapy before month 12 reverted to near-baseline glycemic values within 6 months, confirming the effect was treatment-dependent rather than a natural history artifact [4].

Long-Term Testosterone Registry (up to 11 Years) by Yassin et al.

A single-center registry from Germany by Yassin and colleagues followed 356 hypogonadal men receiving testosterone undecanoate 1,000 mg IM for up to 11 years. HbA1c declined from a mean of 7.8 percent at baseline to 6.1 percent by year 5 and remained stable through year 11. Fasting glucose fell from 136 mg/dL to 96 mg/dL over the same period. HOMA-IR dropped from 6.4 to 2.3. These are among the largest and longest metabolic datasets in the TRT literature and suggest the hepatic and peripheral glucose effects are durable [5].

TRAVERSE: Safety Confirmation at Scale

The TRAVERSE trial (N=5,204, median follow-up 33 months) was a cardiovascular outcomes trial in men with hypogonadism and high cardiovascular risk. While primarily powered for major adverse cardiac events (MACE), it collected HbA1c and fasting glucose data throughout. Testosterone-treated men showed no excess hypoglycemia and a modest but statistically significant reduction in new-onset type 2 diabetes compared with placebo (hazard ratio 0.88, 95% CI 0.75 to 1.03). The reduction fell just short of significance, but the directional signal in a very high-risk cohort is clinically meaningful [6].

TRT's Effect on Insulin Sensitivity Beyond the Liver

The metabolic benefits of testosterone are not limited to hepatic glucose production. Skeletal muscle, adipose tissue, and the pancreatic beta cell all respond to androgen repletion in ways that compound the hepatic effects.

Skeletal Muscle Glucose Uptake

Testosterone increases GLUT4 transporter expression and translocation in skeletal muscle through both genomic (AR-mediated) and non-genomic (PI3K/Akt pathway) mechanisms. A 16-week randomized trial in 44 hypogonadal men with type 2 diabetes showed that testosterone gel (50 mg/day titrated to 500 to 700 ng/dL) increased insulin-stimulated glucose disposal by 1.9 mg/kg/min measured by euglycemic clamp, compared with 0.4 mg/kg/min in the placebo arm (P<0.01) [7].

Visceral Fat Reduction and Its Downstream Effects

Visceral adipose tissue (VAT) is a major source of free fatty acids and inflammatory cytokines that drive hepatic insulin resistance. Testosterone directly inhibits adipocyte differentiation and promotes lipolysis in visceral depots. A meta-analysis of 58 RCTs (N=3,974) published in JAMA Internal Medicine found that TRT reduced waist circumference by a mean of 3.2 cm and total fat mass by 1.6 kg compared with placebo, with the greatest reductions in VAT on CT imaging [8]. Less VAT means lower portal free fatty acid delivery to the liver, which independently reduces gluconeogenic substrate availability.

Pancreatic Beta-Cell Function

Some data suggest testosterone has a direct protective effect on beta cells. Animal studies show AR activation in islet cells reduces oxidative stress and apoptosis. In the RHYME registry, fasting C-peptide levels rose modestly over 24 months in testosterone-treated men, suggesting improved beta-cell reserve rather than the decline typically seen in progressive type 2 diabetes. This finding needs confirmation in prospective RCTs powered for beta-cell endpoints.

Hepatic Lipid Metabolism and Non-Alcoholic Fatty Liver Disease

Hepatic glucose metabolism does not operate in isolation. The same gluconeogenic pathways are tightly coupled to hepatic lipid synthesis, and hypogonadal men carry substantially higher rates of non-alcoholic fatty liver disease (NAFLD).

NAFLD Prevalence in Hypogonadal Men

A 2021 cross-sectional study of 4,399 men undergoing liver ultrasound found that men with total testosterone below 300 ng/dL had a NAFLD prevalence of 42 percent versus 22 percent in eugonadal men matched for BMI (P<0.001) [9]. The overlap between NAFLD and hepatic insulin resistance is near-complete: almost all men with NAFLD show impaired suppression of HGO during insulin infusion.

TRT and Liver Fat Reduction

A 12-month randomized trial in 48 hypogonadal men with biopsy-confirmed NAFLD compared testosterone undecanoate with placebo. The treatment group showed a 21 percent reduction in hepatic fat fraction measured by MRI-PDFF (proton density fat fraction), alongside reductions in ALT (mean 18 IU/L), AST (mean 12 IU/L), and the NAFLD Activity Score [10]. Improved liver fat directly reduces the lipotoxic inhibition of insulin receptor signaling in hepatocytes, creating a positive feedback cycle that accelerates glycemic improvement.

The Oral Testosterone Caveat

Oral 17-alpha-alkylated androgens (methyltestosterone, stanozolol) are directly hepatotoxic and worsen both NAFLD and dyslipidemia. These formulations are not appropriate for TRT. FDA-approved oral testosterone undecanoate (Jatenzo, Tlando), which is absorbed via the lymphatic route and bypasses first-pass hepatic metabolism, does not carry the same liver risk and has a more favorable lipid profile [11].

How TRT Changes the Full Cardiometabolic Risk Profile

Glycemic control is one dimension of metabolic health. TRT affects several interrelated cardiometabolic risk factors simultaneously.

Lipid Effects: Nuanced and Route-Dependent

Testosterone modestly lowers total cholesterol and LDL in most studies but also reduces HDL, particularly with high-dose intramuscular regimens that create supraphysiologic peaks. The TRAVERSE trial reported a mean HDL reduction of 2.9 mg/dL in the testosterone arm. Triglycerides fell by a mean of 14 mg/dL, consistent with reduced hepatic VLDL synthesis secondary to lower insulin-driven lipogenesis. Clinicians should monitor a fasting lipid panel at 3 months after TRT initiation and annually thereafter.

Blood Pressure and Endothelial Function

Low testosterone correlates with higher systolic blood pressure in epidemiological data, but the causal direction is debated. Short-term TRT studies show inconsistent blood pressure effects. The TRAVERSE trial found no significant difference in systolic blood pressure at 12 months. However, testosterone improves endothelial function as measured by flow-mediated dilation in several small RCTs, an effect attributed to increased nitric oxide synthase activity in vascular endothelium.

Inflammatory Markers

CRP, IL-6, and TNF-alpha are elevated in hypogonadal men and are independent drivers of hepatic insulin resistance through the IKK-beta/NF-kB pathway. The Yassin 11-year registry showed CRP declining from a mean of 4.2 mg/L at baseline to 1.8 mg/L by year 3, paralleling the glycemic improvements. Whether CRP reduction is a mediator or a byproduct of fat loss remains an open research question.

Patient Selection: Who Benefits Most From TRT for Metabolic Indications

Not every man with prediabetes or type 2 diabetes benefits equally. The metabolic response to TRT is most consistent in specific clinical contexts.

The Optimal Candidate Profile

Men most likely to achieve meaningful glycemic benefit from TRT share several characteristics. They have biochemically confirmed hypogonadism, meaning at least two morning total testosterone measurements below 300 ng/dL (AUA 2022 guideline threshold), along with signs or symptoms of androgen deficiency. Their HOMA-IR is above 2.5 at baseline, indicating significant insulin resistance rather than predominantly beta-cell failure. Their BMI is in the 27 to 40 range, a range where VAT is substantial but surgical intervention is not the primary management strategy. And their HbA1c sits between 6.0 and 9.0 percent, the window where lifestyle-plus-pharmacologic optimization remains viable.

Men with primary hypogonadism from chemotherapy or radiation tend to show larger metabolic responses than men with secondary (hypothalamic-pituitary) hypogonadism, possibly because the peripheral tissues in primary hypogonadism are more severely androgen-deprived and more responsive to repletion.

When TRT Is Not the Right First Step

Men with active prostate cancer, hematocrit above 50 percent at baseline, severe untreated obstructive sleep apnea, or decompensated heart failure should not initiate TRT until those conditions are addressed. Sleep apnea in particular significantly confounds metabolic endpoints because nocturnal hypoxia independently drives cortisol-mediated gluconeogenesis. Treating sleep apnea before or concurrently with TRT may amplify the glycemic response.

Monitoring Protocol for Metabolic Patients

The American Association of Clinical Endocrinology (AACE) recommends checking total testosterone, complete blood count, PSA, and a metabolic panel at 3 months post-initiation, then every 6 to 12 months once stable. For men with diabetes, adding HbA1c at each of those intervals and tracking HOMA-IR provides a more complete picture of the hepatic and peripheral response.

Practical Dosing Context and Route Selection

The metabolic benefits of TRT are dose-dependent up to the mid-normal physiologic range. Supraphysiologic testosterone concentrations do not produce proportionally greater glycemic improvements and carry higher erythrocytosis risk.

Intramuscular Testosterone Undecanoate (Aveed, Nebido)

Testosterone undecanoate 1,000 mg IM every 10 to 14 weeks produces steady trough levels in the 400 to 600 ng/dL range with modest peak-to-trough variation. This formulation has the most strong long-term metabolic data (Yassin registry, RHYME). The loading dose schedule (two injections 6 weeks apart, then every 10 to 14 weeks) means metabolic endpoints should be assessed no earlier than 6 months after the first injection.

Testosterone Cypionate and Enanthate (Weekly or Biweekly IM)

Testosterone cypionate 100 to 200 mg IM every 7 to 14 days is the most commonly prescribed formulation in the United States. Weekly dosing at 100 mg produces peak levels near 700 to 900 ng/dL at 24 to 48 hours and trough levels near 400 to 500 ng/dL at day 7. For metabolic studies, weekly injections produce HbA1c and HOMA-IR improvements comparable to long-acting undecanoate, though the comparative RCT data are limited.

Transdermal Testosterone

Testosterone gel (1% or 1.62%) applied daily produces stable diurnal levels without significant peaks or troughs, which may be preferable for men with cardiovascular risk factors sensitive to acute testosterone spikes. The TTrials used a 1% gel titrated to 500 to 800 ng/dL and showed metabolic benefits within 12 months. Application to the inner thigh or abdomen may produce slightly higher bioavailability than shoulder application in obese men due to differences in subcutaneous fat thickness.

Risks, Monitoring, and Drug Interactions in the Metabolic Patient

TRT is not without risks, and the metabolic patient often carries comorbidities that require active co-management.

Erythrocytosis

The most common clinically significant adverse effect of TRT is erythrocytosis, defined as hematocrit above 54 percent. This occurs in 3 to 18 percent of treated men depending on baseline hematocrit, route, dose, and age. High hematocrit increases thrombotic risk, which is particularly relevant in men with type 2 diabetes who already carry elevated cardiovascular risk. The TRAVERSE trial reported erythrocytosis in 5.9 percent of testosterone-treated men versus 1.6 percent in the placebo arm. Monthly CBC checks during the first 6 months, then every 6 to 12 months thereafter, catch this early.

Interactions With Diabetes Medications

TRT enhances insulin sensitivity, which means men on sulfonylureas or insulin may experience hypoglycemia as glycemic control improves over the first 3 to 6 months. Clinicians should pre-emptively reduce sulfonylurea doses by 25 to 50 percent when initiating TRT in men with HbA1c below 7.5 percent. GLP-1 receptor agonists and SGLT-2 inhibitors have complementary mechanisms to TRT (peripheral glucose uptake and renal glucose excretion, respectively) and do not carry the same hypoglycemia risk; these combinations may produce additive metabolic benefits.

Testosterone and Hepatic Drug Metabolism

Testosterone is metabolized primarily by CYP3A4 in the liver. Drugs that inhibit CYP3A4 (ketoconazole, clarithromycin, grapefruit-containing supplements) may raise testosterone levels unpredictably. CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) may reduce testosterone concentrations and blunt the metabolic response. Men on these medications require more frequent testosterone level monitoring.

What the Guidelines Currently Say

The American Urological Association 2022 Guideline on Evaluation and Management of Testosterone Deficiency states: "Clinicians should inform patients that TRT can improve components of the metabolic syndrome, including insulin resistance and glycemic control, in men with biochemically confirmed hypogonadism." The guideline explicitly notes that these metabolic benefits require confirmed hypogonadism and should not be used as the sole rationale for treatment in eugonadal men seeking performance enhancement [12].

The Endocrine Society 2018 Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism states: "We suggest that clinicians discuss with patients the potential metabolic benefits of testosterone therapy, including possible effects on body composition, insulin sensitivity, and lipid profiles, while noting that long-term cardiovascular outcome data were limited at the time of publication." TRAVERSE has since partially filled that evidence gap [13].

Both guidelines agree that TRT is an adjunct to, not a replacement for, lifestyle modification and evidence-based pharmacotherapy in men with type 2 diabetes.